Jan Vietor

 

Research Interest

In the context of neurodegeneration and neuroprotection I am focusing on the nuclear receptor related-1 (Nurr1) as biological target. I am studying the medicinal chemistry of the nuclear receptor by developing small molecule ligands as tool compounds. Performing organic synthesis as well as assessing the synthesized compounds with different in‑vitro methods, I try to examine structure activity relationships in order to obtain potent, efficient and selective Nurr1 agonists.

Publications

Nawa, F.; Sai, M.; Vietor, J.; Schwarzenbach, R.; Bitić, A.; Wolff, S.; Ildefeld, N.; Pabel, J.; Wein, T.; Marschner, J. A.; Heering, J.; Merk, D. Tuning RXR modulators for PGC1α recruitment. J. Med. Chem., 2024. DOI

Sai, M.; Vietor, J.; Kornmayer, M.; Egner, M.; López-García, U.; Höfner, G.; Pabel, J.; Marschner, J.; Wein, T.; Merk, D. Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole. J. Med. Chem., 2023, DOI 

Vietor, J.; Gege, C.; Stiller, T.; Busch, R.; Schallmayer, E.; Kohlhof, H.; Höfner, G.; Pabel, J.; Marschner, J.; Merk, D. Development of a Potent Nurr1 Agonist Tool for In Vivo Applications. J. Med. Chem., 2023, 66, 6391–6402 DOI

Helmstädter, M.; Vietor, J.; Sommer, J.; Schierle, S.; Willems, S.; Kaiser, A.; Schmidt, J.; Merk, D. A new FXR ligand chemotype with agonist/antagonist switch. ACS Med. Chem. Lett., 2021, 12, 267–274 DOI